Chugai Secures Japanese Approval for Tecentriq in Rare Thymic Carcinoma
核心洞察
Chugai Pharmaceutical obtained regulatory approval from Japan's MHLW for Tecentriq (atezolizumab) to treat unresectable thymic carcinoma (搜索), addressing a significant unmet medical need.
The approval was based on results from the investigator-initiated phase II MARBLE study conducted in Japan, which evaluated Tecentriq combined with carboplatin and paclitaxel as first-line treatment.
Tecentriq received orphan drug designation for this indication in March 2025 and underwent Priority Review following Chugai's application in May 2025.
Chugai Pharmaceutical Co., Ltd. announced on December 22, 2025, that it has obtained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the anti-cancer agent Tecentriq® (atezolizumab) for the additional indication of unresectable thymic carcinoma (搜索). The humanized anti-PD-L1 (搜索) monoclonal antibody represents a significant advancement for patients with this rare and challenging cancer.
Regulatory Pathway and Designation
Tecentriq received orphan drug designation for this indication from the MHLW on March 31, 2025. Chugai subsequently filed an application on May 14, 2025, which underwent Priority Review, reflecting the urgent medical need for effective treatments in this patient population.
"We are very pleased to be able to deliver Tecentriq as a new treatment option for unresectable thymic carcinoma (搜索). Effective treatment options for this disease are limited, and new therapies have been highly anticipated," said Dr. Osamu Okuda, Chugai's President and CEO.
Clinical Evidence Supporting Approval
The approval is based on results from the investigator-initiated phase II MARBLE study conducted in Japan. The study evaluated the efficacy and safety of Tecentriq in combination with carboplatin and paclitaxel as first-line treatment for patients with unresectable thymic carcinoma (搜索). The combination therapy demonstrated both efficacy and safety in this patient population.
Addressing Unmet Medical Need
Thymic carcinoma (搜索) represents a rare malignancy with limited treatment options, creating a significant unmet medical need for patients and healthcare providers. The approval of Tecentriq for this indication provides a new therapeutic option in a disease area where effective treatments have been scarce.
Dr. Okuda emphasized the company's commitment to supporting patients, stating, "We will continue our efforts to provide information on the proper use of Tecentriq to contribute to the patients with thymic carcinoma (搜索)."
Company Commitment
Chugai Pharmaceutical, positioning itself as a leading company in the oncology field, remains committed to addressing unmet medical needs in cancer treatment with innovative medicines, supporting both patients and healthcare professionals in their fight against cancer.